November 23, 2020
(National Resilience, Inc.), a new company building the world's most advanced
biopharmaceutical manufacturing ecosystem, announced
its launch. RESILIENCE has raised over US$800
million of capital following the recent Series B raise of
approximately US$750 million. Led by ARCH
Venture Partners and 8VC with participation by GV and NEA, investors include
public mutual funds, some of the largest U.S.-based pharmaceutical companies,
foundations, family offices, and pension funds, among others.
Latham & Watkins LLP represents RESILIENCE in the transaction with a corporate deal
team led by Bay Area partners Patrick Pohlen and Miles Jennings, with
Bay Area associates Andrew Bertolli and Taimi Jacobson. Advice
was also provided on antitrust matters by Washington, D.C. counsel Peter
Todaro; and on regulatory matters by Washington, D.C. partners Steven
Croley and Jim Barker.